Vivo Capital related stories
All articles and analysis
Fund briefs recapEmergence, which scored big with the Veeva IPO in October 2013, raises $335 million for its fourth fund; plus other venture-related news from the United States, Asia and Europe
Vivo raises $600.7 mln for eighth fund, Walden closes on $55 mlnVivo Ventures added more capital to its now $600.7 million eighth fund and Walden Venture Capital raised $55 million for its eighth fund, according to documents filed with the SEC.
- VC-backed Ascendis Pharma goes public
Danish biotech firm Ascendis Pharma has raised $108 million for its IPO after pricing its 6 million shares at $18 per share. The stock begins trading Wednesday on the NASDAQ under the ticker symbol "ASND." BofA Merrill Lynch and Leerink Partners are serving as the lead underwriters. Ascendis Pharma's backers include Sofinnova Ventures, OrbiMed, Vivo Capital, Venrock, RA Capital Management and Janus Capital Management.
- Vivo and QuestMark raise fresh capital
Vivo Ventures has raised a $428 million eighth fund while QuestMark Partners announced it received commitments of $152 million toward its fourth fund, according to documents filed with the Securities and Exchange Commission.
- Sofinnova Ventures, OrbiMed, Vivo Capital lead $60 mln funding in Ascendis Pharma
Sofinnova Ventures, OrbiMed and Vivo Capital have led a $60 million Series D funding in Ascendis Pharma, a biotechnology company. Other investors in the funding include Janus Capital Management, Venrock, RA Capital Management, Rock Springs Capital and Sectoral Asset Management. Ascendis Pharma's largest shareholder, Sofinnova Partners, also participated in the funding round. James Healy of Sofinnova Ventures, Jonathan Silverstein of OrbiMed and Albert Cha of Vivo Capital have joined the company's board of directors.
- VC-backed ProNai adds five to senior management staff
ProNAi Therapeutics, a developer of nucleic acid therapeutics, has expanded its senior management team with five additions. Joining the firm are Dr. Angie You as chief business and strategy officer and head of commercial; Wendy Chapman as senior vice president of clinical operations; Chandra Lovejoy as senior vice president of global regulatory affairs and quality; Emma McCann as vice president of program management; and James Smith as vice president of corporate affairs. ProNAi's backers include Vivo Capital, Frazier Healthcare Ventures, OrbiMed Advisors, Adams Street Partners, RA Capital Management, Caxton Alternative Management, Hopen Life Science Ventures, Sectoral Asset Management and Janus Capital Management.
- Coherus BioSciences nabs $55 mln Series C
Coherus BioSciences has raised $55 million in Series C funding. The investors included KKR, Venrock, RA Capital Management, Rock Springs Capital, Fidelity Biosciences, Sofinnova Ventures, Lilly Ventures and Vivo Capital. Based in Redwood City, Calif., Coherus BioSciences is a biologics platform focused on biosimilars.
- ProNAi Therapeutics raises Series D
ProNAi Therapeutics, a developer of novel nucleic acid therapeutics has closed an oversubscribed $59.5 million Series D financing. The round was led by Vivo Capital and included other new investors Frazier Healthcare Ventures, OrbiMed Advisors, Adams Street Partners, RA Capital Management, Caxton Alternative Management, Hopen Life Science Ventures, Sectoral Asset Management and Janus Capital Management.
- Novo A/S leads $18 mln Series B funding in Nora Therapeutics
Novo A/S has led an $18 million Series B funding in Nora Therapeutics, a biotechnology company focused on developing therapeutics to address needs in reproductive medicine. Other participants in the funding round included all Series A investors -- Burrill & Company, Prospect Venture Partners, Rho Ventures and Vivo Capital. Heath Lukatch, partner at Novo Ventures, will join the company's board of directors.
- VC-backed AirXpanders snags $7 mln from GE Capital
AirXpanders has received a $7 million credit facility from GE Capital. Based in Palo Alto, Calif., AirXpanders is a tissue-expansion company focused on breast cancer reconstruction. It is backed by Vivo Ventures, GBS Venture Partners, Prolog Ventures, Heron Capital and Shalon Ventures.